480 reports of this reaction
2.4% of all REMDESIVIR reports
#10 most reported adverse reaction
COVID 19 PNEUMONIA is the #10 most commonly reported adverse reaction for REMDESIVIR, manufactured by Gilead Sciences, Inc.. There are 480 FDA adverse event reports linking REMDESIVIR to COVID 19 PNEUMONIA. This represents approximately 2.4% of all 20,319 adverse event reports for this drug.
Patients taking REMDESIVIR who experience covid 19 pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 PNEUMONIA is a less commonly reported adverse event for REMDESIVIR, but still significant enough to appear in the safety profile.
In addition to covid 19 pneumonia, the following adverse reactions have been reported for REMDESIVIR:
The following drugs have also been linked to covid 19 pneumonia in FDA adverse event reports:
COVID 19 PNEUMONIA has been reported as an adverse event in 480 FDA reports for REMDESIVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 PNEUMONIA accounts for approximately 2.4% of all adverse event reports for REMDESIVIR, making it a notable side effect.
If you experience covid 19 pneumonia while taking REMDESIVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.